Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

281. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma

Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma 25504995 2015 05 01 2016 04 06 2015 05 01 1399-3003 45 5 2015 May The European respiratory journal Eur. Respir. J. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. 1273-82 10.1183/09031936.00152014 This phase 2/3 randomised, parallel-group, placebo-controlled trial investigated oral corticosteroid (OCS)-sparing efficacy, safety and tolerability of nebulised (...) budesonide (Bud) administered with a novel computer-controlled, compressor-driven inhalation system (AKITA) as add-on therapy to Global Initiative for Asthma step 5. Patients (18-65 years) with OCS-dependent asthma were randomised (2:1:1:1) to receive 18-week, twice-daily, double-blind treatment with AKITA inhaled corticosteroid (AICS)-Bud 1 mg, AICS-Bud 0.5 mg, AICS-placebo or open-label Bud 1 mg administered by conventional nebuliser (CN-Bud). OCS doses were tapered until week 14. 199 patients started

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

282. Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial.

Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. 26010632 2015 05 27 2015 05 29 2017 05 26 1538-3598 313 20 2015 May 26 JAMA JAMA Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. 2033-43 10.1001/jama.2015.5024 Soy isoflavone supplements are used to treat several chronic diseases, although the data (...) supporting their use are limited. Some data suggest that supplementation with soy isoflavone may be an effective treatment for patients with poor asthma control. To determine whether a soy isoflavone supplement improves asthma control in adolescent and adult patients with poorly controlled disease. Multicenter, randomized, double-blind, placebo-controlled trial conducted between May 2010 and August 2012 at 19 adult and pediatric pulmonary and allergy centers in the American Lung Association Asthma

JAMA2015 Full Text: Link to full Text with Trip Pro

283. Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids.

Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids. BACKGROUND: Asthma is the most common chronic medical condition among children and is one of the most common causes of hospitalisation and medical visits. Poorly controlled asthma often leads to preventable exacerbations that require additional medications, hospital stays, or treatment in the emergency department.Long-acting beta2-agonists (LABA) are the preferred add (...) -on treatment for children with asthma whose symptoms are not well controlled on inhaled corticosteroids (ICS). The US Food and Drug Administration has issued a 'black box' warning for LABA in asthma, and now recommends that they be used "for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved". OBJECTIVES: To compare the effect on asthma control and adverse effects of stepping down to inhaled corticosteroids (ICS)-only

Cochrane2015

285. Omalizumab Treatment for Adults and Children with Allergic Asthma

Omalizumab Treatment for Adults and Children with Allergic Asthma Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered (...) with Allergic Asthma: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines DATE: 9 March 2015 CONTEXT AND POLICY ISSUES Asthma is chronic inflammatory disease of the airways that affects 300 million individuals worldwide and is associated with significant mortality and morbidity. 1 Allergic asthma is the most common form of asthma, where exacerbations are triggered by allergens such as dust mites and pollen and are attributable to immunoglobulin E (IgE)-mediated mechanisms. 2 Asthma

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

286. Eczema and indoor environment: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase 2.

Eczema and indoor environment: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase 2. BACKGROUND: Numerous studies have reported a positive association between damp housing conditions and asthma, but little is known about indoor environmental exposures in relation to childhood eczema. We aimed to specifically investigate the effect of indoor mould and dampness on eczema risk in the International Study of Asthma and Allergies in Childhood (ISAAC). METHODS

Lancet2015

287. Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data.

Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data. BACKGROUND: Incomplete understanding of mechanisms and clinicopathobiological heterogeneity in asthma hinders research progress. Pathogenic roles for T-helper-type 17 (Th17) cells and invariant T cells implied by murine data have yet to be assessed in man. We aimed to investigate the role of Th17 and mucosal associated invariant T (MAIT) cells in airway inflammation (...) ; to characterise associations between diverse clinical and immunological features of asthma; and to identify novel multidimensional asthma endotypes. METHODS: In this single-centre, cross-sectional observational study in the UK, we assessed volunteers with mild-to-severe asthma and healthy non-atopic controls using clinical and physiological assessment and immunological sampling of blood, induced sputum, endobronchial biopsy, and bronchoalveolar lavage for flow cytometry and multiplex-electrochemiluminescence

Lancet2015

288. Asthma and Exercise-Induced Bronchoconstriction in Athletes.

Asthma and Exercise-Induced Bronchoconstriction in Athletes. Asthma and exercise-induced bronchoconstriction in athletes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 25671256 Format MeSH and Other Data E (...) -mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Feb 12;372(7):641-8. doi: 10.1056/NEJMra1407552. Asthma and exercise-induced bronchoconstriction in athletes. , . PMID: 25671256 DOI: [Indexed for MEDLINE] Publication type MeSH terms Substance Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links

NEJM2015

289. Association between asthma and risk of developing obstructive sleep apnea.

Association between asthma and risk of developing obstructive sleep apnea. IMPORTANCE: Obstructive sleep apnea (OSA) is more common among patients with asthma; whether asthma is associated with the development of OSA is unknown. OBJECTIVE: To examine the prospective relationship of asthma with incident OSA. DESIGN, SETTING, AND PARTICIPANTS: Population-based prospective epidemiologic study (the Wisconsin Sleep Cohort Study) beginning in 1988. Adult participants were recruited from a random (...) sample of Wisconsin state employees to attend overnight polysomnography studies at 4-year intervals. Asthma and covariate information were assessed during polysomnography studies through March 2013. Eligible participants were identified as free of OSA (apnea-hypopnea index [AHI] of <5 events/h and not treated) by 2 baseline polysomnography studies. There were 1105 4-year follow-up intervals provided by 547 participants (52% women; mean [SD] baseline age, 50 [8] years). EXPOSURES: Questionnaire

JAMA2015 Full Text: Link to full Text with Trip Pro

290. A cluster-randomized trial shows telephone peer coaching for parents reduces children`s asthma morbidity

A cluster-randomized trial shows telephone peer coaching for parents reduces children`s asthma morbidity 25445827 2015 05 09 2015 07 23 2016 12 15 1097-6825 135 5 2015 May The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity. 1163-70.e1-2 10.1016/j.jaci.2014.09.033 S0091-6749(14)01369-4 Childhood asthma morbidity remains significant, especially in low-income children (...) . Most often, asthma management is provided by the child's primary care provider. We sought to evaluate whether enhancing primary care management for persistent asthma with telephone-based peer coaching for parents reduced asthma impairment and risk in children 3 to 12 years old. Over 12 months, peer trainers provided parents with asthma management training by telephone (median, 18 calls) and encouraged physician partnership. The intervention was evaluated in a cluster-randomized trial of 11

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

291. Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations?

Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2015

292. Australian Asthma Handbook

Australian Asthma Handbook Australian Asthma Handbook | Australian Asthma Handbook Know what you're looking for? Australia's National Guidelines for Asthma Management The Australian Asthma Handbook provides best-practice, evidence-based guidance translated into practical advice for primary care health professionals. The Handbook is proudly published by Australia's lead asthma authority, the National Asthma Council Australia. 1 2 3 1 2 3 1 2 3 Australian Asthma Handbook v1.2 Version 1.2 (...) continues to set the standard for practical, evidence-based advice for primary care chronic disease management. Stay up to date Join our health professional community and stay informed on Handbook updates Disclaimer The Australian Asthma Handbook is the national guidelines for asthma management in primary care. It has been developed for use by Australian health professionals. Use of this website is subject to disclaimers that we encourage you to . © National Asthma Council Australia 2017 site by

Clinical Practice Guidelines Portal2015

293. Diagnosis and management of asthma in preschoolers

Diagnosis and management of asthma in preschoolers Can Respir J Vol 22 No 3 May/June 2015 135 SPECiAL Ar TiCLE ©2015 Pulsus Group Inc. All rights reserved Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper Francine M Ducharme MD MSc 1 , Sharon D Dell MD 2 , Dhenuka Radhakrishnan MD MSc 3 , Roland M Grad MDCM MSc FCFP 4 , Wade TA Watson MD MEd 5 , Connie L Yang MD MSc 6 , Mitchell Zelman MDCM 7 1 Departments (...) -mail ctsinfo@lung.ca FM Ducharme, SD Dell, D Radhakrishnan, et al. Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper. Can Respir J 2015;22(3):135-143. Asthma often starts before six years of age. However, there remains uncer- tainty as to when and how a preschool-age child with symptoms suggestive of asthma can be diagnosed with this condition. This delays treatment and contributes to both short- and long-term morbidity

Canadian Thoracic Society2015

294. Nucala (mepolizumab) - For use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older.

Nucala (mepolizumab) - For use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala (mepolizumab) Lyophilized Powder for Subcutaneous Injection U.S. Department of Health and Human Services Search FDA Submit search Nucala (mepolizumab) Lyophilized Powder for Subcutaneous Injection Nucala Company: GlaxoSmithKline LLC Application No.: 125526 Approval Date: 11/04/2015 Persons with disabilities having problems accessing the PDF files below

FDA - Drug Approval Package2015

295. Asthma: tiotropium (Spiriva Respimat)

Asthma: tiotropium (Spiriva Respimat) Asthma: tiotropium (Spiriva Respimat) Asthma: tiotropium (Spiriva Respimat) Evidence summary Published: 3 March 2015 nice.org.uk/guidance/esnm55 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Two replicate randomised (...) controlled trials (RCTs; total n=912) of identical design evaluated tiotropium (Spiriva Respimat) in adults with poorly controlled asthma and persistent airflow obstruction who were already treated with an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA). Tiotropium improved peak and trough forced expired volume in 1 second (FEV1) and lengthened the time to first severe exacerbation compared with placebo. Differences between add-on therapy with tiotropium and placebo in patient

National Institute for Health and Clinical Excellence - Advice2015

296. High-dose inhaled corticosteroids in asthma

High-dose inhaled corticosteroids in asthma Asthma: medicines safety priorities Asthma: medicines safety priorities Key therapeutic topic Published: 15 January 2015 nice.org.uk/guidance/ktt5 pathways Options for local implementation Options for local implementation Review all people with asthma who have been prescribed more than 12 short-acting reliever inhalers in the previous 12 months. Monitor asthma control at every review. If control is suboptimal: confirm the person's adherence (...) to prescribed treatment, review the person's inhaler technique, review if treatment needs to be changed and ask about occupational asthma and/or other triggers, if relevant. Inhaled corticosteroids (ICS) are the first-choice regular preventer therapy for adults and children with asthma. Adjust the dose over time, aiming for the lowest dose required for effective asthma control. Consider decreasing maintenance therapy when a person's asthma has been controlled with their current maintenance therapy

National Institute for Health and Clinical Excellence - Advice2015

297. Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler)

Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) Asthma in adults: beclometasone/formoterol dry Asthma in adults: beclometasone/formoterol dry powder inhaler (F powder inhaler (Fostair NEXThaler) ostair NEXThaler) Evidence summary Published: 27 January 2015 nice.org.uk/guidance/esnm53 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in January 2015. See summaries of product characteristics (...) (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Fostair NEXThaler is an inhaled corticosteroid (ICS)/ long-acting beta-2 agonist (LABA) combination dry powder inhaler containing extrafine beclometasone/formoterol. Evidence from an 8-week randomised controlled trial suggests that in adults with stable asthma it is non-inferior to the pressurised metered dose inhaler (Fostair), and superior to non-extrafine beclometasone dry powder inhaler

National Institute for Health and Clinical Excellence - Advice2015

298. Benralizumab for uncontrolled asthma - second line

Benralizumab for uncontrolled asthma - second line Benralizumab for uncontrolled asthma – second line Benralizumab for uncontrolled asthma – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Benralizumab for uncontrolled asthma – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review (...) . 2015 Authors' objectives Benralizumab is intended to be used as second line therapy for the treatment of patients with uncontrolled asthma. If licensed, benralizumab will offer an additional treatment option for patients with this condition. Benralizumab is a fully humanised anti-interleukin-5 receptor (IL-5R) monoclonal antibody which blocks the binding of IL-5 to the specific α-chain of the IL-5 receptor. IL-5 stimulates the production, activation and maturation of eosinophils, which is thought

Health Technology Assessment (HTA) Database.2015

299. Reslizumab for eosinophilic asthma

Reslizumab for eosinophilic asthma Reslizumab for eosinophilic asthma Reslizumab for eosinophilic asthma NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Reslizumab for eosinophilic asthma. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Reslizumab is intended to be used (...) for the treatment of eosinophilic asthma in adults who are inadequately controlled on inhaled corticosteroids. If licensed, it will offer an additional treatment option for patients with eosinophilic asthma. Reslizumab is a monoclonal antibody which acts as an interleukin-5 (IL-5) receptor antagonist. IL-5 stimulates the production, activation and maturation of eosinophils. Infiltrating tissue eosinophils are potent proinflammatory leukocytes containing granule-derived basic proteins, lipid mediators, cytokines

Health Technology Assessment (HTA) Database.2015

300. Bronchial thermoplasty for the treatment of severe persistent asthma

Bronchial thermoplasty for the treatment of severe persistent asthma Appl Applic Date o Context at www 1. An Ass thermop Departm 2. After co and cos for BT populat effectiv 3. MSAC severe a is defin combin procedu airways broncho compris The pat severe a that con lication N cant: of MSAC c t for decisio w.msac.gov. Purpose o essment Re plasty (BT) ment of Hea MSAC’s a onsidering t st-effectiven for the treat tion, its plac veness and r Summary noted that t asthma desp ned as the m ned with a lo (...) ure involvin s through a oscope unde ses three pro tient popula asthma who nfirmation r Pub No. 1384 s onsiderat on: MSAC m au of applica eport reques for severe p alth in Octo advice to t the availabl ness of bron tment of sev ce in the clin resulting un y of consid this applicat pite treatme maximal inha ong-acting b ng the delive single use c er moderate ocedures w ation for the ose asthma s required tha lic Sum – Bronc severe p Bos ion: MS makes its ad tion and l sting Medic persistent a ber

Medical Services Advisory Committee2015